Why do we not have an HIV vaccine and how can we make one? (original) (raw)

• Desrosiers, R.C. Non-human primate models for AIDS vaccines. AIDS 9 (Suppl. A), S137–S141 (1995).
  Article Google Scholar
• Burton, D.R. A vaccine for HIV type 1: the antibody perspective. Proc. Natl. Acad. Sci. USA 94, 10018–10023 (1997).
  Article CAS Google Scholar
• Trkola, A. et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-lgG. J. Virol. 69, 11, 6609–6617 (1995).
  CAS PubMed PubMed Central Google Scholar
• Moore, J.P. & Ho, D.D. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9 (suppl A), S117–S136 (1995).
  PubMed Google Scholar
• Rowland-Jones, S., Tan, R. & McMichael, A. The role of cellular immunity in protection against HIV infection. Adv. Immunol. 65, 448–455 (1997).
  Google Scholar
• Jassoy, C. & Walker, B.D. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Springer Sem. Immunopathol. 18, 341–354 (1997).
  Article CAS Google Scholar
• Oldstone, M.B.A. HIV versus cytotoxic T lymphocytes: the war being lost. N. Eng. J. Med. 337, 1306–1308 (1997).
  Article CAS Google Scholar
• Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205–211 (1997).
  Article CAS Google Scholar
• Rowland-Jones, S.L. & McMichael, A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr. Opin. Immunol. 7, 448–455 (1995).
  Article CAS Google Scholar
• Hasenkrug, K.J. & Chesebro, B. Immunity to retroviral infection: the Friend virus model. Proc. Natl. Acad. Sci. USA 94, 7811–7816 (1997).
  Article CAS Google Scholar
• Baldridge, J.R., McCraw, T.S., Paoletti, A. & Buchmeier, M.J. Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells. J. Virol. 71, 755–758 (1997).
  CAS PubMed PubMed Central Google Scholar
• Planz, O. et al. A critical role for neutralizing-antibody-producing B cells, CD4+ T cells, and interferons in persistent and acute infections of mice with lymphocyte choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc. Natl. Acad. Sci. USA 94, 6874–6879 (1997).
  Article CAS Google Scholar
• Rosenberg, E.S. et al. Vigorous HIV-1-specific CD4+ T cell response associated with control of viremia. Science 278, 1447–1450 (1997).
  Article CAS Google Scholar
• Ezzell, C. The monkey's got AIDS: what now for live AIDS vaccines? Journal of NIH Research 9, 21–22 (1997).
  Google Scholar
• Stott, E.J. & Schild, G.C. Strategies for AIDS vaccines. J. Antimicro. Chemother. 37 Suppl. B, 185–198 (1996).
  Article CAS Google Scholar
• Sharpe, S.A., Whatmore, A.M., Hall, G.A. & Cranage, M.P. Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-re-vertant virus. J. Gen. Virol. 78, 1923–1927 (1997).
  Article CAS Google Scholar
• Shibata, R., Siemon, C., Czajak, S.C., Desrosiers, R.C. & Martin, M.A. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J. Virol. 71, 8141–8148 (1997).
  CAS PubMed PubMed Central Google Scholar
• Deacon, N.J. et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988–991 (1995).
  Article CAS Google Scholar
• Connor, R.I. et al. Immunological and virologicat analyses of persons infected by human immunodeficieny virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72, 1552–1576 (1998).
  CAS PubMed PubMed Central Google Scholar
• Haynes, B.F. HIV vaccines: where we are and where we are going. Lancet 348, 933–937 (1996).
  Article CAS Google Scholar
• VanCott, T.C. et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomericgp120. J. Virol. 71, 4319–4330 (1997).
  CAS PubMed PubMed Central Google Scholar
• Excler, J.-L. & Plotkin, S. The prime-boost concept applied to HIV preventative vaccines. AIDS 11, S127–S137 (1997).
  PubMed Google Scholar
• Liu, M.A. Nature Med. (1998). See this issue [Insert page #s].
• Graham, B.S. et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of current AIDS vaccines. J. Infect. Dis. 177, 310–319 (1998).
  Article CAS Google Scholar
• Corey, L. et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J. Infect. Dis. 177, 301–309 (1998).
  Article CAS Google Scholar
• Bloom, B.R. The highest attainable standard: ethical issues in AIDS vaccines. Science 279, 186–188 (1998).
  Article CAS Google Scholar
• Nossal, G. Host immunobiology and vaccine development. The Lancet 350, 1316–1319 (1997).
  Article CAS Google Scholar
• Berman, P.W. et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. Infect. Dis. 176, 384–397 (1997).
  Article CAS Google Scholar